electroCore, Inc. (ECOR) Earnings Call Transcript & Summary

November 4, 2026

NASDAQ US Health Care Health Care Equipment and Supplies earnings 60 min

Earnings Call Speaker Segments

Thomas Errico

executive
#1

Thank you, operator. Good afternoon, everyone, and thanks for being with us on electroCore's Third Quarter 2026 Earnings Call. What defined this quarter was making our foundation stronger — in leadership, in commercial execution, and in regulatory clarity. These results deepen my conviction and my enthusiasm regarding where the company stands right now. It was a record quarter for electroCore — the highest net sales and the smallest operating loss in our history as a company. Beneath those numbers, management is constructing a commercial organization built to grow profitably at a far bigger scale. As with any transformation, the changes have been considerable, and we believe the changes we have carried out have laid a foundation that puts electroCore in position for accelerated growth and for an inflection point in positive adjusted EBITDA in 2027. For me, among the most exciting developments is the progress we are making opening new markets. On October 27, we submitted our 510(k) premarket notification to the FDA, seeking clearance for our Quell wearable neurostimulation device for treating chemotherapy-induced peripheral neuropathy, or CIPN; this filing follows the breakthrough designation from the FDA in January 2022, which covers reduction of moderate to severe symptoms of chemotherapy-induced peripheral neuropathy persisting for at least 6 months after chemotherapy ended. Should clearance come, Quell could provide a new nondrug option to patients experiencing CIPN — an important step for electroCore and for those patients seeking symptom relief. Along with continued progress in commercial execution and financial discipline, this new opportunity demonstrates that the path forward is stronger today than at any point in the last several years. Josh will take you through the quarter and where we are headed. Mike will walk you through the plans implemented for growth and the measures we track in the field, and Josh will then return with the financials. Josh?

Joshua Lev

executive
#2

Thank you, Tom, and good afternoon, everyone. In this quarter we posted net sales of $9.7 million, a record, which is roughly 12% higher than the same period last year, and we had the smallest operating loss in the company's history, with our adjusted EBITDA loss better by almost $1.4 million during the quarter, which came in ahead of what we had expected. Gross margin rose to 88.5%, and our loss from operations shrank to $1.6 million. GAAP net loss was better by $1.3 million, or $0.13 per share, compared with $3.1 million, or $0.33 per share, in the second quarter, and adjusted EBITDA loss came in at a company-record $700,000; we increased revenue while spending less to achieve it. Further into this call, I'll take you through all of the financial details. I'd like to be candid regarding the direction in which this company is moving. Our management of this business is not oriented toward quick wins. Our aim is to build revenue over the long haul that is sustainable, recurring, and profitable. Every choice we made this year was intentional, taken with the awareness that it could sacrifice near-term growth in return for success and profitability down the road. Truvaga is the most obvious example. Revenue from direct-to-consumer Truvaga fell compared with a year earlier, and that result is exactly the one we were aiming for. The count of competitors bidding on Truvaga's own branded search term has risen 60%, and our cost per click has climbed roughly 42%. We had the option to keep spending in order to grow the top line, but that would have been empty calorie revenue, propping up the revenue line while moving us further away from profitability; so we decided not to chase it, and our return on advertising spend rose 8% year-over-year. This shows how we think about generating revenue, not merely growing the top line, but doing so with profitability in mind. The improvement in our P&L is early evidence that this approach works. Revenue is up, costs are down — and when a business expands while spending less, it's becoming stronger. Now for guidance: we're lowering our full-year 2026 revenue outlook to a range of $39 million to $42 million, versus our earlier forecast of more than 30% year-over-year growth. The shift here is one of timing rather than direction. The changes we made in our sales organization are reaching the full field more slowly than we'd anticipated. Consequently, the pickup we had anticipated for the back half of 2026 we now look for in 2027. Those changes were made because they're the right ones for the business. That brings me to the reason we feel confident about 2027. This comes down to three themes. The first is coverage: the more VA accounts we have staffed, the more facilities will have a rep on site selling both gammaCore and Quell. The second is accountability: with smaller territories, each account has one clear owner and a clear benchmark for results. The third is early evidence that the model is working. Mike will take you through the leading indicators we're seeing in the field, among them the way reps added since June are bringing in more revenue from their accounts than those accounts generated before they came on board. On top of that, our 510(k) for chemotherapy-induced peripheral neuropathy, or CIPN, is currently under FDA review. If we get the green light in 2027, Quell revenue can expand along two routes: making sure our reps use Quell across the entire coverage area, and obtaining an additional indication for chemotherapy-induced peripheral neuropathy — and to the best of our knowledge, no pharmaceutical or medical device option today carries a specific indication for CIPN. In our view, those moves will help drive faster revenue growth throughout all of 2027, and our preliminary guidance for 2020 revenue growth is 30% to 40% year-over-year; we intend to tighten that range and share more commentary at the appropriate time later on. We said this last quarter, and our current model still holds: should that growth come through, we think the operating leverage built into our model — gross margins in the upper 80s on a streamlined cost base — combined with the cash we already have and our financing resources, means we can get to our first fiscal quarter of positive adjusted EBITDA by the end of 2027 without launching a new dilutive equity capital financing transaction. The next 12 months are all about execution, and I'd like Mike to walk you through how we'll do that. Mike?

Michael Fox

executive
#3

Thanks, Josh. Good afternoon, everyone. Josh walked through our thinking on how revenue accelerates. My role is to ensure the company and our field organization are structured to capture revenue and spot fresh opportunities for expansion. What brought us to this point won't carry us to where we're headed. So across the past several months, we've been building stronger processes and raising expectations, which will produce sharper focus and better metrics around how we source, hire, train, coach, lead and measure results. I'd like to share concrete metrics showing why our confidence in the trajectory for 2027 and beyond is so high. Every month, we monitor five imperatives: developing leadership talent and sales efficiency, the number of new accounts using our products, new patient orders (which we refer to as NPOs), the count of prescribers, and finally, our national refill rate. I'd like to spotlight the metrics behind three of those imperatives, which reinforce our confidence in accelerating revenue growth. First, on leadership talent and sales efficiency: we divided the Vice President of Sales position into two area vice presidents — one for the East and one for the West — who together oversee our six regions. We promoted a proven internal colleague from inside our company to head the East area. Our West area Vice President was hired from outside the company and came on board in October. He has extensive expertise running medical sales organizations, covering the federal market as well as growing market share and revenue. In October we brought on 2 new regional sales directors, and a third will join shortly. This provides the field with dedicated leadership, stronger accountability, and more chances for essential field coaching and expertise. In places where we could implement these changes, they have demonstrated their effectiveness; during the third quarter, both our Southeast and Northeast regions achieved the highest quarterly revenue in their histories. In the Southeast, we moved territories to high-performing independent representatives who concentrate on increasing utilization of both Quell and gammaCore, and results came quickly. With fresh leadership now on board, the Southeast serves as our template, and we're positioned to extend that approach across the country with greater speed and better results. The performance of our newly onboarded independent representatives illustrates this well. From June onward, the reps we brought in generated an average of roughly $210,000 per month in VA revenue during quarter 3. Compared with the $160,000 monthly figure those territories had produced previously, that represents a 30% gain, and in October the group is now tracking toward $300,000 per month. Their September revenue came in 62% above June 2026 levels. What gives me the most encouragement is these early indicators from the new representatives. Both revenue and new accounts are climbing faster, requiring about 2 months rather than the 6 to 7 months it took before. By month three, new patient starts hit 3.4 per account, versus only 0.3 for accounts onboarded earlier. These figures are preliminary, yet they suggest the trajectory we anticipated: quicker starts, quicker account growth, and deeper penetration within accounts. Second, VA account penetration and impact. In Q3 alone, we added 7 VA accounts that had never bought any of our products previously — up roughly 5% from the second quarter — and the proportion of staff facilities lacking gammaCore on hand dropped to 28% from 34% between June and September. Revenue is also becoming less concentrated: using the same metric we shared with you last quarter, our top 15 accounts represented 54% of revenue in the second quarter and 51% in the third. Moving forward, we'll report on our top 30 accounts — approximately the top quarter of the VA base — which accounted for 73% of VA revenue in the second quarter and 71% in the third. No single facility made up more than 10% of our VA net sales during the third quarter. Quell fibromyalgia had its strongest month ever on October 26, and we surpassed 1,000 VA patients prescribed Quell in 2026 alone. At present, over 70% of VA accounts aren't prescribing Quell — which tells us, for Quell, that a sizable opportunity is still there. Looking at all products combined, NPOs from the VA as a whole rose 21% year-over-year during the third quarter, which means more veterans are receiving treatment — that's our ultimate metric and our focus. Third, patient refills. Among the clearest signals of patient benefit are refills. Revenue from refills increased 10% versus the second quarter, marking the highest level in company history. Our national refill rate sits at 42% year-to-date through September, and we're aiming to drive it above 70%; patient training and prescriber confidence are the levers. We're running a trial of a fresh patient education program focused on getting people to stick with treatment more closely, which leads to improved results for patients and, as a result, stronger refill numbers. What we're aiming for now is lifting patient training and adherence to a better benchmark—something we consider necessary for reaching a 70% refill rate. That effort is already in motion, and we anticipate the first refill rate improvements appearing in Q4, with additional gains expected in early 2027. Turning to operations: Level Government Services, the unit responsible for generating sales for the VA and Department of Defense, represented roughly 91% of our VA orders in September 2026, compared with about 57% in June '26. That reflects a considerable change in how many orders flow through Level since our August announcement of plans to direct more sales its way. Level now serves as the main channel for every prescription product sale we make to the VA and Department of Defense. This gives us the strongest partner for federal distribution and is expected to reduce the associated transaction fees on those direct sales by 3%. Beyond that, it releases our own staff to focus on fresh and developing markets. In those regions, we are cultivating ties through multiple commercial and federal avenues in which our offerings can benefit patients, and we disclose them once they turn into revenue. During Q3, Pfizer held conversations about coverage with its external California market. We have additionally participated in the Quell assessment in California, and the results of their internal valuation have encouraged us. During Q3, our work with the Department of Defense and TRICARE involved substantial effort to connect with key stakeholders and hold mutually beneficial conversations for active military personnel and their families; we've identified pilot regions for federal workers' compensation, though additional process steps and validation must be completed before further discussions proceed. Contracts have been engaged and started with consultants for both VA Women's Health and first responders. Each consulting group offers extensive network expertise, and conversations are underway with prominent national opinion leaders capable of advancing adoption and progress of our devices. Both opportunities excite us, and we'll share metrics as they evolve in Q4 and through 2027. Every one of those metrics leaves part of the picture out, and our transformation is still underway, yet these are the numbers we manage the business by, and we'll go on reporting them so investors can keep following how we're doing. As we roll these strategies out across the national sales team, we anticipate growth that is stronger, longer-lasting and more profitable. With that, I'll hand things back to Josh for the financials.

Joshua Lev

executive
#4

Thank you, Mike. electroCore posted net sales of $9.7 million for the 3 months ended September 30, 2026, versus $8.7 million in the same period of 2025 — roughly a 12% rise year over year. That $1 million gain came mainly from higher net sales of the Quell fibromyalgia products acquired from NeuroMetrix, Inc. in May 2025, along with Prescription gammaCore, both of which are sold to the VA. Through the rest of 2026, the company plans to produce its sales in the VA channel via its agreement with Lovell. Gross profit rose $1.1 million to $8.6 million, up from the third quarter of 2025. Gross margin rose to 88.5%, up from 86% in the same period last year and from 86.5% in Q2, mostly because of a favorable product mix. R&D expense was $400,000 in Q3 2026, compared with $700,000 in Q3 2025 and $800,000 in Q2 2026. That decrease was primarily due to the timing of open positions, professional fees, and development costs. SG&A expense totaled $9.7 million, essentially unchanged from the year-ago period and below the $10.1 million recorded in Q2 2026. Sales and marketing increased $300,000 versus the prior year, mainly from selling expense that supported the $1 million growth in net sales. G&A costs came down by $200,000, driven mostly by reduced professional fees. For the three months that closed on September 30, 2026, total operating expenses reached $10.1 million, versus $10.4 million during the same three-month period ending September 30, 2025. Our GAAP net loss in Q3 2026 amounted to $1.3 million, compared with $3.4 million in Q3 2025. Within that GAAP net loss, other income contributed a gain of roughly $400,000 related to settling indemnification claims, along with a $100,000 income tax benefit stemming from a favorable adjustment to our United Kingdom tax provision after we changed our transfer pricing policy. For Q3 2026, the net loss per share came in at $0.13, versus a net loss of $0.40 in Q3 2025. Adjusted EBITDA net loss for Q3 2026 totaled $700,000, compared with an adjusted EBITDA net loss of $2 million in Q3 2025 — roughly $1.4 million better, a 67% year-over-year improvement. Adjusted EBITDA net loss is a non-GAAP financial measure. The use of non-GAAP financial measure in today's press release for additional information and a reconciliation to GAAP net loss. As of September 30, 2026, total cash, cash equivalents and marketable securities stood at approximately $7.5 million, versus approximately $10 million at June 30, 2026. Inventories rose to $4 million, compared with $1.6 million at year-end, since we stocked up to back the growth we expect in our prescription business. That move—aimed at speeding up revenue growth in the near term—plus greater patient involvement via in-home delivery made up a large share of the cash we used this quarter. Before finishing, I'd like to leave you with three key points. For us, this quarter set a record. Net sales reached $9.7 million, roughly 12% higher, gross margins were 88.5%, and we posted our smallest operating loss ever, while adjusted EBITDA loss reached its lowest level in company history. Revenue has climbed even as costs have come down. Our focus is on durable revenue over the long haul rather than quick wins we pursue. We're intentionally moving toward the kind of revenue that gets us nearer to profitability, and that improvement in profitability is arriving sooner than we had forecast. Because we think a portion of the acceleration we expected in the back half of 2026 will now show up in 2027 instead, we're updating our full year 2026 revenue guidance to a range of $39 million to $42 million. Having more fully staffed VA accounts, tighter territories with explicit ownership, and recently hired reps who are already producing more from their accounts—all of this gives us visibility and confidence in revenue growth that will speed up the 30% to 40% rise in 2027 revenue compared with 2026 revenue, along with further Quell adoption should our CIPN 510(k) gain clearance. Our liquidity and capital position are set out in our Form 10-Q. Getting to our first quarter of positive adjusted EBITDA by the end of 2027 depends on revenue ramping up and ongoing operating efficiencies. We're also looking at ways to refinance the term loan we already have, including pushing back when principal repayments come due, which we'd expect to give our cash runway and balance sheet extra support while we carry out this plan. No agreements have been signed, and there's no guarantee we'll reach any. Still, putting it all together, as we noted last quarter, if these actions are executed successfully, our present model indicates that, together with the cash we have on hand and our financing resources, we believe we can be in a position to hit our first quarter of positive adjusted EBITDA by the end of 2027 without having to enter into a new dilutive equity capital financing transaction. Our strategy is locked in, our people are ready, and the coming twelve months will be focused on delivering on it. I appreciate the time you've given us and your ongoing backing. We're eager to share our progress with you in the following quarter; at this point, I'd like to turn things over for questions. Operator?

Destiny Buch

analyst
#5

This is Destiny, filling in for Jeff. I've got quite a few questions lined up, so I'll try to keep them a bit condensed. Could we begin with maybe — and Mike, this one may be more for you; but how are you thinking about the sales force when it comes to maximum revenue contribution, right? So it moved from that 160 number up to 210. At what point do you think these reps would be kind of at capacity? And maybe I'll begin there since I have a second part to it.

Michael Fox

executive
#6

Thanks for the question; and it's a great one. As you know, accounts vary in size, number of vets, number of specialties. Saturation is a very difficult word to define in the VA because of the markets we're in, specifically with migraine and fibromyalgia, including some of the subspecialties like women's health. The way we're looking at this right now, I don't think we have to worry about saturation as much as we're taking care of the patients where they're at. Community care is a large component of federal business, which means the veterans are being treated outside the VA, but have the benefits to get our products through prosthetics; so at this moment, I think we do have some accounts that are large in comparison to other ones; but when we talk to providers in those accounts, there are still a lot of uncared for patients that are spread across the VA space; so I would say our goal is to have about 14 new patients per month per account total between both products. That would be a good goal; but I don't know about the word saturation. That really would depend on the market of that account, for example, Dallas, versus like Iron Mountain, Wisconsin. They're totally different in space. But we have goals for every account in every territory, especially with the diversification of the number of providers; so hopefully, that gives you somewhat of an answer, even though I know saturation is hard to define.

Destiny Buch

analyst
#7

No, that's genuinely quite useful. And you've already covered what I was going to ask next. That was about the monthly target for patient starts. I believe I heard you say 14 — is that right?

Michael Fox

executive
#8

Yes. What we're looking at — yes, roughly 2 patients weekly for gammaCore, the migraine product, and around 1.5 to 2 weekly for fibromyalgia, depending on the account; but those are the expectations we're putting to the sales force. Naturally, we'd like them to beat that, but those are the goals we're setting.

Destiny Buch

analyst
#9

So now, shifting focus a bit more toward the CIPN opportunity. From a commercial standpoint, how are you approaching that? Will it be possible to use the same sales force you already have? Or do you believe a somewhat more specialized group might be needed? I realize it's early, but broadly speaking, what's your thinking there?

Michael Fox

executive
#10

Regarding the chemotherapy-induced peripheral neuropathy specifically, the 510(k)?

Destiny Buch

analyst
#11

Yes.

Michael Fox

executive
#12

That is an excellent question. We are being assessed for that right now, exactly as you mentioned—treating peripheral neuropathy within the VA represents a very large market. Yet once you begin looking at chemotherapy-induced cases, we are pinpointing some distinct targets, particularly involving oncology and the various kinds of nurse practitioners connected to those therapies; so we are in the process of evaluating. I feel confident that we can capture a meaningful number of opportunity accounts using the sales force we currently have, though there could be a need for a more specialized or more sharply focused approach given the oncology emphasis of that product, which will be determined as we move nearer to launch.

Destiny Buch

analyst
#13

And then one final thing from me. Regarding your DTC channel, I was curious — it was encouraging to see ROAs improve. How should we think about that when it comes to revenue contribution and growth, if there is any? If you could expand on that a bit more, that would be really helpful.

Joshua Lev

executive
#14

Destiny, this is Josh. Thanks so much for asking. The short answer is that we're really staying consistent with what we said earlier in the year — we're not going to chase unprofitable revenue. What we're aiming to do is change how we think about driving revenue, so that we move closer and closer to adjusted EBITDA positive toward the end of 2027. So with that in mind, we believe our Truvaga revenue will grow year-over-year. We've said we believe we were going to do that. That said, our goal isn't to grow it at the same, call it, triple digits it grew 2025 over 2024. That growth is going to slow down dramatically, because the profitability of each revenue dollar we generate through that growth is going to be higher; so in terms of how you think about it, what I'd say is our expectation is that year-over-year it will be up somewhat, but the profitability we're seeing on the back end is really our focus. We're not going to just chase what we mentioned in the script — empty calories, right? Empty calorie revenue. We're really going to focus on how we get each dollar of contribution to carry a higher contribution margin than it did previously.

Swayampakula Ramakanth

analyst
#15

My first question concerns the guidance itself. Your guidance is $39 million to $42 million. That means you need to deliver somewhere between 6% and almost 30% in sequential growth, and we haven't really witnessed that over the last 3 or 4 quarters; so what makes you confident that the business is now positioned to deliver at least the low single digit — low double-digit sequential growth?

Joshua Lev

executive
#16

RK, let me take that first, and then I'll hand it over to Mike. Mike shared plenty of KPIs in today's remarks. But really, it boils down to 2 main things. First, I'd say, the number of VAs — or more specifically, the count of people we have calling on the VA — we believe will be, I'd say, fully staffed starting this October. As Mike explained, we've altered how our sales organization is structured. We split the organization so that we now have 2 area vice presidents. We have 6 regional sales directors. So first and foremost, the most important point is that during the third quarter, what we established is the need to keep finding new people — people capable of being more productive and people who have built networks and relationships within the VA that help sell our products. That's the first thing. And then second, which really just continues that thought, the people we've onboarded and the newer individuals and resources selling our product have actually proven more productive than those we had here historically, and they're getting up to speed faster than what we saw before; so from our perspective, I think we're genuinely enthusiastic about the caliber of talent we brought in over the last couple of months. Those individuals have demonstrated an ability to sell products historically, but they're really demonstrating an ability to sell our products too. And their ability to get up and running faster and generate sales more quickly is something Mike covered in some KPIs earlier; but Mike, is there anything you'd like to add?

Michael Fox

executive
#17

Absolutely, Josh, thanks. RK, there are numerous factors behind my confidence, though as Josh mentioned, the people dimension carries the most weight. Beyond that, we have internal tools—targeting capabilities plus actionable dashboards and reports—that assist our reps in pinpointing patients due for refills. The data they can act on is fresher and considerably more robust, letting them engage providers so those providers know when a patient is responding well to therapy and needs a refill. Refill rate is very much a priority for us. The forecast we've provided reflects two things coming together: stronger momentum in starting new patients on therapy, plus an improved refill rate consistent with what our clinical data show for this product. Those factors, taken together with everything Josh covered, explain where the forecast figures land. I hope that addresses your question, RK.

Swayampakula Ramakanth

analyst
#18

Now, just to follow up on the guidance question itself. As we head into the next year, are any revenues from the CIPN indication factored into that growth trajectory you're guiding for? Or is all of this based on the work you've done so far with the sales team, along with the products and indications you currently have in the bag?

Joshua Lev

executive
#19

Yes, I view that as being upside. When it comes down to it, we filed the 510(k). The earliest we'd hear back from the FDA on that 510(k) probably won't be until, say, the back half of the first quarter, which means from a sales standpoint, actual sales within, say, fiscal 2027 really wouldn't begin generating until the back half of the year; so from our perspective, it's gravy when it comes to CIPN revenue. That said, we do believe it could, in theory, open up new call points for us, since we'd have the ability to start talking about it. Keep in mind, our product for CIPN for Quell specifically already carries breakthrough designation. So given that we filed, given that we hold the breakthrough designation we received for CIPN. We see it as an opportunity to open up for sales of Quell, which is part of the 2027 forecast, but anything specific to CIPN would really be incremental to that.

Swayampakula Ramakanth

analyst
#20

Regarding Quell specifically, could you help us get a handle on how Quell has performed sequentially—order cadence and any organizational transitions you're going through right now? And Josh, I'm also just trying to get clear on this: my understanding is that Quell and the CIPN were initially submitted for 510(k), then something shifted in the interim, and then it went back to 510(k) again; so could you walk me through that history of going back and forth with the FDA and tell us how confident we should be that 510(k) is the correct route here?

Joshua Lev

executive
#21

Yes, absolutely; I'll take that question, and then I'll hand it to Mike to address the cadence of Quell revenue—where we're seeing it and where we expect it to go; so as for the 510(k) that was filed, you're right. Originally, when—before we bought the company, before we bought NeuroMetrix, the former management there was holding conversations with the FDA about possibly making the submission. Without going too deep into the details, the guidance that was basically given was to pursue the de novo pathway for CIPN. When we acquired the business, we didn't necessarily believe that was necessarily correct. I mean, we also—not only does the Quell product for fibromyalgia already exist. So the predicate was already in place. We also had the breakthrough designation, which we viewed as part and parcel of what the objective of having a breakthrough designation would be, which is to help streamline the ability of new innovative products to come to FDA and get approved, so in our opinion the 510(k) pathway probably made a lot more sense. Fast forward a few years, the members of the FDA responsible for reviewing what would be the CIPN filing are different. And the new team involved took a look once we began having conversations with them. We actually filed the de novo at their request. And the new team on board took a look at it and said, we don't believe this really should go down the de novo pathway based on who we are and what our mandate is, we think a 510(k) pathway is probably more appropriate given where you are and given the breakthrough designation. So what they advised was that we recall the de novo, which we did, and then resubmit as a 510(k), which we did, and we announced late last week; as for whether that makes us feel more confident or less confident? — at the end of the day, we're still talking about the FDA. The data itself hasn't changed. I do believe it's a good sign that the FDA review team has taken a look at the product and said, look, we don't think there is a de novo pathway here. We believe the existing safety profile from the predicate device, Quell, is likely adequate; so on that front—we're opting to stay optimistic, but it's still the FDA, correct? Even with a breakthrough designation, even with the government and the FDA and this particular political party—though that's an interesting remark to make on November 4, though that's been shifting on its own; but the current administration was quite eager to try to move a new innovative product forward. So we're treating it as good news. But when all is said and done, it's still the FDA. They'll still follow their process, and we're still working with the government agency on it. So I suppose we always prepare for the worst, hope for the best, but we are hopeful that the information we supplied and the team reviewing it does recognize the benefits and the data demonstrating the potential benefits to CIPN sufferers, mainly because no medical device or pharmaceutical products are cleared specifically or approved specifically for CIPN. So it would be the first, which would be great; regarding the cadence of the business, I'll just leave you with this tidbit before I hand it over to Mike, which is that in October, we surpassed 1,000 Quell patients, users, which is amazing; and I believe October was our largest Quell month in company history. So with that good news, I'll let—I'll hand it over to Mike. I'll let Mike elaborate a little bit.

Michael Fox

executive
#22

Yes, RK, just so I can get a clearer picture — when you mention cadence, I'd like to know what you'd want me to expand on a bit more.

Swayampakula Ramakanth

analyst
#23

I wanted to ask how orders have been trending as time goes on. When it comes to growth in orders, what does the picture look like? And from the roughly $1.2 million per quarter we're at now, where do you see this product heading? How far could it climb, leaving CIPN aside? Naturally, CIPN might represent a separate market added on top of that — and what's your view on that market, the CIPN one?

Michael Fox

executive
#24

Let's begin with Quell fibromyalgia considered on its own, because that's what we can do at the moment. CIPN by itself presents a very exciting opportunity, both for the patients we can help and because of the unmet need. To give you a sense of the figures at this point, October was quite strong, as Josh mentioned. October's dollar revenue and new patient orders were higher than January and February of this year added together. So growth is occurring. Is the growth rate one that pleases us? I doubt we're ever pleased. Still, we're content that the trends are heading the way they ought to. There's plenty of work ahead of us and plenty of VAs. That fits with the approaches we're taking on other fronts inside the company. As far as pace goes, Quell's adoption in the federal space has been quite encouraging, though we clearly must continue finding additional avenues for reaching more of these VAs, since at present an excessive number of VAs have not yet engaged with Quell. Those are precisely the places where we're concentrating more effort through additional reps or stronger coaching, so that account coverage is more balanced by year-end. Still, thus far the trajectory looks favorable, RK. One thing worth keeping in mind is that this product originated at a company that operated independently. Given the fibromyalgia market and everything this product offers, I genuinely think it could serve as a stand-alone product for a company. We're fortunate to have it as either a second product or the first of two products, depending on how you rank gammaCore Quell. The technology is really impressive, and I'm eager to see how far it can go.

Jeremy Pearlman

analyst
#25

First off, I'd like to spend a moment on the guidance. It looks like on the prior earnings release call, you were pointing toward adjusted EBITDA of 27% for the third quarter; and with this release, it appears that's now by the end of '27. And you're guiding to 30%, 40% revenue growth and lower OpEx. So maybe what are some of the underlying assumptions — why does profitability seem to have shifted somewhat?

Joshua Lev

executive
#26

Yes. Great question, Jeremy. Thanks for joining. It's really just a function of timing. A portion of the revenues we had hoped to see within the 2026, we now see arriving and picking up pace in 2027. So it comes down basically to a shift in the timing.

Jeremy Pearlman

analyst
#27

And then just — I know you brought up some of the gains from the sales reps this quarter. Is it that — are those gains, is that more a reflection of how productive the actual sales reps are, or maybe also just the natural maturation of the existing accounts, some combination? Maybe if you could break that down a bit.

Michael Fox

executive
#28

Yes. I can tell you that you're exactly right. I'd say yes to all of it. We do have some very strong reps who've been here a long time, and helping them grow and expand the number of providers in their existing accounts has been a big focus. Some of them had only been selling gammaCore, and now we have them selling both Quell and gammaCore. But we've also replaced some account coverage with new 1099s, new regional sales directors with relationships, better access and better expertise within the VA. So I'd say it's a combination of everything; we're assessing every single account and every single person that sells our products on a monthly basis; so there are a lot of different spots to be taken care of, but we're welding everything as tight as we can when we find where the weak spots are and sharpening them when we need to be sharper.

Jeremy Pearlman

analyst
#29

And perhaps a bit more on that same subject. There's likely some level of attrition from the actual — patients are using the gammaCore. What might you do to perhaps curb some of that and keep patients subscribing for longer?

Michael Fox

executive
#30

That's an excellent question. The main thing we discovered with medical devices, particularly at-home devices where patients administer them on their own, is the steady chance for us to do what we preach — hold up the mirror so they can see that sometimes they lose sight of having had 12 to 15 migraines a month, and now they experience only 6 to 8, simply to confirm the quality of life and the benefits they're getting, along with some of the secondary effects of our therapies too that they might not be noticing; also to ensure providers keep becoming advocates and that they grasp the value of staying with these products. In the VA, for instance, plenty of triptans and migraine medications are used — what they call rescue meds. Many physicians recognize the value of cutting medications for these patients, especially those on things outside of label within the antidepressant class or angiolytics and such, just to keep migraines controlled on top of their triptans. So the fewer medications they take, the better for everyone. And so as we keep working toward higher compliance rates and higher refill utilization, really the ultimate aim is to help patients become healthier and happier with a more fulfilled life, as we owe our service members for all they've done for us. So that's the plan.

Jeremy Pearlman

analyst
#31

And then just one last question about the 510(k) submission. How big is the addressable market if that gets approved? How many patients? And will you be selling — is that going to be inside the VA? Or will it be separate, outside of that?

Joshua Lev

executive
#32

So look, hopefully the answer is both, right? That would be ideal. Again, like I said earlier, there's no other approved product, pharmaceutical or medical device, currently on the market for CIPN specifically. So we see that as a great opportunity for us to enter what's known as a blue ocean, or a market that doesn't have an opportunity. As for the overall opportunity itself, just to give you very high-level numbers, about 50% of people who go through chemotherapy have some form of a neurotoxin, and about 50% of those people end up with some form of CIPN. So the total addressable market, I think, in the United States would be roughly 600,000 to 700,000; within the VA it would be roughly 15,000 to 20,000; but they're large markets, and more importantly, they're large markets with no other alternative. So being able to leverage the science, the technology, the safety profile of what we can offer based off of our bioelectronic technologies — we don't want to commit to not entering a larger market; but right now, as you and all of our investors know, the VA is primarily where we sell; and that is probably going to be, if you will, the lowest hanging fruit as a way for us to start.

Michael Fox

executive
#33

Yeah, I was about to mention that — you brought up addressable markets. We intend to pursue that market. So the federal space isn't where we'll halt; however, as you're aware, beyond the VA things take somewhat more time, since you begin examining reimbursement coverage and similar matters. Still, given an opportunity of this kind, we will certainly explore beyond the federal space. That's simply what I wanted to add. We'll take that in various directions. How it plays out and where that reimbursement originates, we'll keep you updated.

Fozia Ahmed

analyst
#34

I’d like to start with a question about the CIPN program. What’s your expected timing for an additional information request from the FDA? Also, as I understand it, two studies backed the data for the CIPN. Are any additional studies underway or being planned to support this submission? And on top of that, do you think that open 483 form could have an impact on when the CIPN application gets submitted?

Joshua Lev

executive
#35

Thanks for the questions, Fozia. Regarding the time line: typically, the FDA states that with a 510(k) submission, their approach is to aim to respond within 90 days—after 90, what they refer to as review days—to provide you with an answer. So what review days actually mean is that they receive the application, and typically it takes roughly two to three weeks for them to go through it and confirm it's complete. Once it's complete, it moves on to final review. In that final review stage, the VA — meaning the FDA — can go back and forth and pose questions. Every time the FDA raises a question about the data, the clock stops. Then, when the question gets answered — whether the company answers it — the clock stays stopped. So the FDA's target date is generally 90 review days, but really that's only their target. If everything goes as well as it possibly could — and I want to stress this is the optimistic case — the earliest we'd get any word back from them on this would be during the back half of Q1. As for the data, at the moment there isn't any plan set up on our end to run further trials for that application.

Fozia Ahmed

analyst
#36

Also, regarding the impact of that open Form 483, could it potentially push back the timeline?

Joshua Lev

executive
#37

I don’t believe so. That’s a fair question. The 483 related quite specifically to the over-the-counter NeuroMetrix product that was sold back in 2017. Therefore, our view is that it won’t cause a delay; that said, it’s the FDA, and it remains entirely their prerogative to pose as many safety and efficacy questions as they wish.

Analyst

analyst
#38

Josh and Mike, I'd like to congratulate both of you for steering this company toward a fresh direction and for assembling a dynamic sales team — bold, and I believe it will turn out very well indeed. I personally had a hand in the Quell acquisition for electroCore. At the time it was bought, they had a substantial over-the-counter business with Quell, which at one point hit $15 million annually. Would ElectroCore want to take another look at going over the counter with Quell?

Joshua Lev

executive
#39

Dr. Theophilus, thank you so much first of all for being here. Your backing of this company has truly been without equal. So we genuinely appreciate you and everything you've done; for those listening on the call who might not be aware, Dr. Theophilus is not merely an investor. He is also a founder of the technology. So we're very grateful to you and for the support you've extended to the company. Now, regarding what you asked, we think a market could exist for an over-the-counter style of product for Quell. In our filings we refer to it as Quell 2.0 or Quell over-the-counter; we had originally stated our intent was to launch that during this year. However, in light of the 483 letter that Fozia mentioned a bit earlier, that has slipped. So since the over-the-counter effort, the 483 commentary really centered on how we think about the over-the-counter product, that product itself has been pushed back. We do — I should say, we would like to move ahead and launch some version of an over-the-counter-based product using Quell; but the timing for that at present is to be determined, pending not only some of the 483 commentary, but also, really, returning to what we said earlier, which is — our goal, above all, is to pursue profitable revenue. And we need to confirm that the market exists in a way that lets us make those sales, yet do it profitably and move us closer and closer to that adjusted EBITDA profitability toward the end of next year. And that will be, in a sense, our guiding star.

Walter Schenker

analyst
#40

A while back the company released a study — a clinical trial run together with the Air Force — that showed the benefits for healthy participants in physical performance as well as mental performance. You've published a number of those, again. I just want to bring us up to date, and I know Mike has had plenty of other things on his plate, but more or less how does he see the opportunities beyond headaches and fibromyalgia, into TAC-STIM or other police forces, government, sports, and all the other areas where enhanced performance is probably a good thing.

Michael Fox

executive
#41

Yes, I completely agree. When I saw the published research on the prescription devices, and beyond that the work Dr. Stat and numerous others had done on technology specifically for vagus nerve stimulation, that was among the primary reasons I joined this company. You brought up a significant subject there with the Air Force Research Lab. Without a doubt, seeing that data was extremely exciting. Just so you're aware, obviously that data can be applied to other kinds of high-stress roles. Air traffic controllers represent another opportunity as well, and discussions have been taking place. Since Q2 wrapped up, we’ve concentrated heavily on first responders, aiming to pinpoint where this could help beyond active-duty military — specifically other individuals whose roles keep them in a state of intense sympathetic and parasympathetic activation, carrying substantial trauma and stress. Yes, that's correct — there's a great deal of knowledge that can be passed along; we simply need to get that message out to the right people. One of the consultants we engaged in Q3 is closely connected with many police SWAT units in the New Jersey area as well as the Port Authority, and the aim is to explore whether we can keep collaborating with them on what they need and also pursue some of the other opportunities in the military and among those facing comparable high-stress conditions. So I hope that addresses your question — but yes, I agree. That's not the kind of information you'd want to simply leave sitting on a shelf. Many others ought to see it.

Joshua Lev

executive
#42

Thank you, operator — we genuinely appreciate it. And before we wrap up, I'd like to pull back briefly from the quarterly numbers. This platform rests on genuine science, and as a first-to-market offering, we've only just started to reach the market. In the areas where we've implemented commercial changes, those changes are delivering, and we now have the leadership team in place to extend them nationwide. It isn't merely our belief that growth lies ahead; we're seeing what we consider to be early signals in the figures themselves. So from our standpoint, the timing has shifted, yet our conviction remains unchanged. Turning those early signals into durable outcomes is now our task; so I'd like to use this moment to express thanks to our shareholders for their patience and their ongoing backing. Naturally, to our patients, our providers and our partners — thank you for placing your trust in us with your care. And above all, to our team, thank you for turning up each day with the discipline and the ambition this opportunity calls for. We appreciate everyone joining today's call, and we look forward to speaking with you again next quarter.

Operator

operator
#43

This concludes today's call. Thank you for your participation.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete electroCore, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to electroCore, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in electroCore, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.